In Glycogen Storage Disease type II, also called Pompe Disease, the deficiency of the lysosomal enzyme acid α-glucosidase leads to a disease whose treatment is mainly based on enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA). The gene discussed is GAA; the disease is Glycogen storage disease due to acid maltase deficiency.